✦ LIBER ✦

The epidemiology of Alzheimer’s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

✍ Scribed by Kristine Yaffe; Michael Tocco; Ronald C. Petersen; Catherine Sigler; Leah C. Burns; Christel Cornelius; Ara S. Khachaturian; Michael C. Irizarry; Maria C. Carrillo

Book ID: 118467886
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 193 KB
Volume: 8
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2011.12.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimal design of clinical trials for dr

Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease

✍ Richard C. Mohs; Claudia Kawas; Maria C. Carrillo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 188 KB

Commentary on “Optimal design of clinica

Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease”

✍ Eric R. Siemers 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 71 KB

PL-05-02: The evolution of Alzheimer's d

PL-05-02: The evolution of Alzheimer's disease clinical trial design

✍ Paul S. Aisen 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

The statistical development of endpoints

The statistical development of endpoints for Alzheimer's disease clinical trials

✍ Raghavan, Nandini 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Commentary on “Optimal design of clinica

Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer℉s disease.” Biochemical biomarkers of late-life dementia

✍ Christopher M. Clark; Domenico Pratico; Lesley M. Shaw; Susan Leight; Sharon X. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Clinical trials with the cholinergic dru

Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT)

✍ Albert Wettstein; René Spiegel 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 216 KB

The muscarinic agonist RS 86 was administered to patients with Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT) in a series of controlled clinical trials. Daily doses were up to 3.0 mg orally for a maximum duration of 18 weeks. RS 86 produced typical peripheral cholinergic e